Materials Healthcare Sector

Gossamer Bio

Market Cap: US$268.1m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

Alumis

Market Cap: US$265.5m

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Tvardi Therapeutics

Market Cap: US$259.7m

Operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases.

Quantum-Si

Market Cap: US$258.7m

A life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS).

Palvella Therapeutics

Market Cap: US$256.5m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Monte Rosa Therapeutics

Market Cap: US$255.9m

A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.

Inozyme Pharma

Market Cap: US$255.0m

A clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function.

Vanda Pharmaceuticals

Market Cap: US$254.0m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Allogene Therapeutics

Market Cap: US$253.7m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

SANUWAVE Health

Market Cap: US$252.9m

Operates as a medical device company in the United States and internationally.

Cerus

Market Cap: US$252.3m

Operates as a biomedical products company.

Nuvectis Pharma

Market Cap: US$251.7m

A clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Tango Therapeutics

Market Cap: US$248.2m

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

Atea Pharmaceuticals

Market Cap: US$248.2m

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.

ZimVie

Market Cap: US$247.9m

Develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide.

Verano Holdings

Market Cap: CA$341.7m

Operates as a vertically integrated multi-state cannabis operator in the United States.

Corvus Pharmaceuticals

Market Cap: US$246.7m

A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

Tristel

Market Cap: UK£183.7m

Develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally.

Lifecore Biomedical

Market Cap: US$245.5m

Operates as an integrated contract development and manufacturing organization in the United States.

Oncology Institute

Market Cap: US$244.0m

An oncology company, provides various medical oncology services in the United States.

MaxCyte

Market Cap: UK£180.7m

A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

Jade Biosciences

Market Cap: US$242.4m

Operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Tactile Systems Technology

Market Cap: US$241.8m

A medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.

Astria Therapeutics

Market Cap: US$240.4m

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

Rezolute

Market Cap: US$239.1m

A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Aardvark Therapeutics

Market Cap: US$238.7m

A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Mayne Pharma Group

Market Cap: AU$369.7m

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Tenax Therapeutics

Market Cap: US$238.2m

A clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

Aquestive Therapeutics

Market Cap: US$237.4m

Operates as a pharmaceutical company in the United States and internationally.

Animalcare Group

Market Cap: UK£176.6m

Develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets.

Ocugen

Market Cap: US$236.5m

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.

Third Harmonic Bio

Market Cap: US$235.1m

A biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.

Creative Medical Technology Holdings

Market Cap: US$234.7m

A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.

Silence Therapeutics

Market Cap: US$234.3m

A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

ProKidney

Market Cap: US$232.2m

A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

Foghorn Therapeutics

Market Cap: US$230.8m

A clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.